In the animal health sector,
Zoetis Inc. (ZTS) has been the subject of numerous investment maneuvers. Multiple firms have either increased, decreased, or initiated their holdings in Zoetis, such as
M&G Plc,
Choate Investment Advisors, and
Lord Abbett & CO. LLC. However, the company draws mixed reactions from investors, as evidenced by its fluctuating stock performance. In Q1 2024, Zoetis presented a robust growth in revenue and net income, surpassing Wall Street estimates. Notably, Zoetis saw a
60% return over the past five years. However, recent concerns over arthritis drugs potentially impacting pets negatively affected its stock prices. Zoetis is also undergoing a European probe over potential competition rule breaches related to dog pain medication. Despite these challenges, Zoetis retains favor in JPMorgan's view. Further, some analysts still view Zoetis as a quality investment and defend its relative performance amidst stock market perturbations.
Zoetis ZTS News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 21 Jul 2024 15:22:03 GMT -
Rating 2
- Innovation 4
- Information 8
- Rumor 2
